AmerisourceBergen ( ABC) is often overlooked as the middle-man in the pharmaceutical industry. The company is one of the largest drug wholesalers in North America, which is a business that carries razor- thin gross margins of only 4%. But what Amerisource lacks in profitability, it makes up for in volume, posting north of $66 billion of revenue last year.

The stock was upgraded Wednesday from Neutral to Buy at Merrill Lynch. The analyst cited the company's low valuation and solid price increases in branded drug pricing for the call. Still, Wall Street has a relatively cool outlook for the shares, with just four out of 13 analysts surveyed by Bloomberg rating AmerisourceBergen a Buy.

At Wednesday's closing price of $38.53, the stock is trading at 12 times expected fiscal 2009 (ending September) earnings of $3.21 This represents a 28% discount to the company's historical average valuation over the past decade, and marks the lowest multiple the stock has received in three years. With that in mind, I'm here to answer readers' questions: Should you buy it? Does AmerisourceBergen have the cure for investors' woes in this volatile environment?

The Right Active Ingredients

The company posted better-than-expected third-quarter results July 24. AmerisourceBergen earned 73 cents a share, which was 7 cents ahead of the consensus analyst estimate. Revenue grew 14.5% year-over-year to $17.51 billion, coming up $120 million less than expected. Still, management is expecting its third straight annual double-digit earnings gain in fiscal 2009.

In addition to improved industry pricing, AmerisourceBergen is achieving this growth by cutting costs. The company is also in the process of selling its workers' compensation division (PMSI), which had been a drag on earnings.

If you liked this article you might like

Stocks Under $10 Portfolio: An Energy Play, a Rate Hike and Rebounding Markets

Stocks Under $10 Portfolio: Earnings and Yellen in the Spotlight

Stocks Under $10 Portfolio: Consumer Staples Overbought

These 2 'Dogs of the Dow' Will Have Their Day in 2017